RBC Capital downgraded Bellus Health (BLU) to Sector Perform from Outperform with a price target of $14.75, down from $21 after the company reached an agreement to be acquired by GSK plc (GSK). The deal is demonstrating validation for Bellus’s lead asset camlipixant as a best-in-class P2X3 antagonist and the market opportunity of refractory chronic cough, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BLU:
- Bellus Health downgraded to Sector Perform from Outperform at RBC Capital
- Bellus Health downgraded to In Line from Outperform at Evercore ISI
- GSK to acquire Bellus Health for $14.75 per share
- Bellus Health Surges after Acquisition by GSK for $2 Billion
- Bellus Health management to meet with Piper Sandler